【摘要】 他克莫司是目前器官移植后的一线免疫抑制药物，同时也应用于很多非移植疾病的治疗。由于他克莫司个体差异大，治疗窗窄，个体化给药研究非常有必要。群体药代动力学在个体化给药方面具有很大优势。本文旨在总结他克莫司在非移植性疾病患者中的群体药代动力学及其影响因素研究，探讨他克莫司在非移植患者中的个体化治疗，为临床合理用药提供参考。更多还原

【Abstract】 Tacrolimus is the first immunosuppressive choice for organ transplantation. It is also used in the immunotherapy of many non-transplant diseases. Because of its large individual variabilities and narrow treatment window, the individualized administration for tacrolimus taking advantage of population pharmacokinetics is necessary. This article aims to summarize population pharmacokinetics studies of tacrolimus in patients with non-transplant diseases and its influencing factors, and to provide a reference for rational use of tacrolimus.更多还原